Europe High Potency API's Market Size- By Type, By Synthesis, By Therapeutic Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Europe High Potency API's Market Introduction and Overview

According to SPER market research, 'Europe High Potency API's Market Size- By Type, By Synthesis, By Therapeutic Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Europe High Potency API's Market is predicted to reach USD 13.48 billion by 2033 with a CAGR of 8.95%.

The pharmacological compounds with high potency are those that show effects at very low doses. Their keen interest in the state-of-the-art medications under development underscores their significance and potential uses. The use of high potency active pharmaceutical ingredients (HPAPI) in the treatment of serious illnesses is growing in the healthcare industry because they are more effective at much lower dosage levels than standard APIs.

High Potency Active Pharmaceutical Ingredients (HPAPIs) were a major industry in Europe prior to the COVID-19 pandemic. Due to reduced manufacturing capacity, lockdown procedures, and disruptions in international supply chains, the production and delivery of HPAPIs faced difficulties throughout the region during the epidemic.

Scope of the Report:

Report Metric Details

Market size available for

years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Type, By Synthesis, By Therapeutic Application

Regions covered France, Germany, Italy, Spain, United Kingdom, Rest of Europe

Companies Covered AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Mylan Inc., Novartis International AG, Pfizer, Inc., and Sanofi.

Europe High Potency API's Market Segmentation:

By Type: Based on the Type, Europe High Potency API's Market is segmented as; Innovative high potency API's, Generic high potency API's.

By Synthesis: Based on the Synthesis, Europe High Potency API's Market is segmented as; Biotech high potency API's, Synthetic high potency API's.

By Therapeutic Application: Based on the Therapeutic Application, Europe High Potency API's Market is segmented as; Oncology, Glaucoma, Hormonal Balance.

By Region: This research also includes data for France, Germany, Italy, Spain, United Kingdom, Rest of Europe.

Product Code: PHAR2410

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe High Potency API's Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Europe High Potency API's Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe High Potency API's Market

7. Europe High Potency API's Market, By Type (USD Million) 2020-2033

7.1. Europe High Potency API's Market Size, Share and Forecast, By Type, 2020-2026
7.2. Europe High Potency API's Market Size, Share and Forecast, By Type, 2027-2033
7.3. Innovative high potency API's
7.4. Generic high potency API's

8. Europe High Potency API's Market, By Synthesis (USD Million) 2020-2033

8.1. Europe High Potency API's Market Size, Share and Forecast, By Synthesis, 2020-2026
8.2. Europe High Potency API's Market Size, Share and Forecast, By Synthesis, 2027-2033
8.3. Biotech high potency API's
8.4. Synthetic high potency API's

9. Europe High Potency API's Market, By Therapeutic Application (USD Million) 2020-2033

9.1. Europe High Potency API's Market Size, Share and Forecast, By Therapeutic Application, 2020-2026
9.2. Europe High Potency API's Market Size, Share and Forecast, By Therapeutic Application, 2027-2033
9.3. Oncology
9.4. Glaucoma
9.5. Hormonal Balance

10. Europe High Potency API's Market Forecast, 2020-2033 (USD Million)

10.1. Europe High Potency API's Market Size and Market Share

11. Europe High Potency API's Market, By Region, 2020-2033 (USD Million)

11.1. Europe High Potency API's Market Size and Market Share By Region (2020-2026)
11.2. Europe High Potency API's Market Size and Market Share By Region (2027-2033)
11.3. France
11.4. Germany
11.5. Italy
11.6. Spain
11.7. United Kingdom
11.8. Rest of Europe

12. Company Profile

12.1. AbbVie Inc.
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Boehringer Ingelheim
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Bristol-Myers Squibb
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Eli Lilly and Company
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. F. Hoffmann-La Roche Ltd.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Merck & Co., Inc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Mylan Inc.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Novartis International AG
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Pfizer, Inc.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Sanofi
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others